查詢結果分析
來源資料
相關文獻
- Intraluminal Mucin Pool in Mucinous Gastric Adenocarcinoma: A Case Report
- 胃癌之流行病學特徵及危險因子
- Dispute of Extended Lymph Node Dissection for Gastric Cancer
- 源自胃癌的克魯根堡氏瘤:十年臨床經瞼
- 胃癌化學治療之進展
- Pregnancy Associated with Gastric Carcinoma
- 20-MHz Ultrasonic Probe to Identify Early Gastric Cancer Suitable for Endoscopic Mucosal Resection
- 胃癌復發併吸收不良症候群
- 一位胃癌瀕死病患生理、心理反應及需求
- 癌症感受性基因之基因型與胃癌的相關性研究
頁籤選單縮合
題名 | Mitomycin C (MMC) with Weekly 24-Hour Infusions of High-Dose 5-Fluorouracil and Leucovorin in Patients with Advanced Gastric Cancer=MMC合併每週24小時高劑量5-FU及LV注射於晚期胃癌病人 |
---|---|
作者 | 陳仁熙; 林永昌; 廖繼鼎; 王正旭; 廖宗琦; | 書刊名 | 長庚醫學 |
卷期 | 26:6 2003.06[民92.06] |
頁次 | 頁433-439 |
分類號 | 415.527 |
關鍵詞 | 胃癌; Gastric cancer; Mitomycin C; 5-fluorouracil; Leucovorin; |
語文 | 英文(English) |
中文摘要 | 背景:我們已經報告過使用每週24小時高劑量5-FU及LV注射於晚期胃癌病人的經驗,可以達成33%反應率及中位存活7個月。探討MMC加入每週24小時高劑量5-FU及LV注射是否可以增加反應率及中位存活時間。 方法:從1998年5月至2000牛12月期間,共有37位廣泛性胃癌未曾化學治療病人接受本治療。其中有20位男性和17位女性,中位年為58歲(範圍:21至73歲)。本治療方法為:每週使用5-FU2600 mg/m2和LV 100 mg/m2混合於門診攜帶型幫浦24小時注射連續6週再休息2週,MMC 10mg/m2和LV 100mg/m2於第一週注射,每8週一次。此治療特續直到疾病惡化、無法接受之毒性或病人拒絕治療為止。 結果:總共進行404次5-FU/LV治療,平均10次治療。反應率為40.5%(15/37),其中有5.4%(2/37)達到完全緩解。時間至疾病惡化為4.5月,中位存活期為8個月。所有病人都接受毒性評估,少於10%病人有第三級或第四級毒性。 結論:MMC合併每週24小時高劑量5-FU及LV注射於晚期胃癌病人具有中度控制能力而且有可以接受之毒性。 |
英文摘要 | Background: We have reported a 33% response rate with 5-fouroruracil/leucovorin (5-FU/LV) treatment along with a median survival of 7 months in patients with advanced gastric cancer. Subsequently, mitomycin C (MMC) became our target agent for the combination because of its activity towards gastric cancer. Methods: From May 1998 to December 2000, a total of 37 chemo-na?ve patients with advanced gastric cancer were included. There were 20 men and 17 women with a median age of 58 (range, 21-73) years. The regimen consisted of 2600 mg/m2 5-FU and 100 mg/m2 LV admixed in an outpatient infusion pump administered for 24 hours ever week for 6 weeks, followed by a 2-week break; then 10 mg/m2 MMC was given once every 8 weeks. The treatment continued until disease progression or unacceptable toxicity was noted, or the patient refused. Results: In total, 404 treatments of 5-FU/LV were given. The mean number of treatments was 10 (range, 1 to 24), the intent to treat response rate was 40.5% (15/37) with 5.4% (2/37) showing a complete response. The median time to disease progression was 4.5 months. The median survival time was 8.0 months. All of the patients were evaluated for toxicity. Less than 10% of the patients developed grade III/IV toxicity. Conclusion: MMC with weekly 24-hour infusions of high-dose 5-FU and LV produced moderate activity in patients with advanced gastric cancer, and patients showed acceptable toxicity. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。